Kiniksa Pharmaceuticals Ltd (KNSA)vsUnited Therapeutics Corporation (UTHR)
KNSA
Kiniksa Pharmaceuticals Ltd
$48.42
-1.65%
HEALTHCARE · Cap: $3.99B
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 320% more annual revenue ($3.17B vs $754.04M). UTHR leads profitability with a 40.6% profit margin vs 9.7%. UTHR trades at a lower P/E of 20.2x. UTHR earns a higher WallStSmart Score of 57/100 (C).
KNSA
Buy53
out of 100
Grade: C-
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.3%
Fair Value
$197.77
Current Price
$48.42
$149.35 discount
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Earnings expanding 145.5% YoY
Conservative balance sheet, low leverage
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 57.0x leaves little room for execution misses.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.57 — expect wider price swings.
KNSA is growing revenue faster at 55.5% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 53/100), backed by strong 40.6% margins. KNSA offers better value entry with a 77.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a pioneering biopharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapies. Its lead candidate, KPL-404, is a monoclonal antibody specifically engineered to modulate immune responses, showcasing its potential in treating various autoimmune disorders. With a robust clinical pipeline and strategic partnerships bolstering its research and development efforts, Kiniksa is positioned for sustained growth in the competitive biopharmaceutical landscape. The company's steadfast commitment to innovation and reimagining treatment paradigms presents a compelling opportunity for institutional investors seeking impactful investments in transformative healthcare solutions.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?